Halozyme Therapeutics

Yahoo Finance • 13 hours ago

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) Following Appreciation

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities hit a record high in the third quarter, fueled by continued gains... Full story

Yahoo Finance • 5 days ago

This Biotech Stock Is Up 50% in 2025, But Redditors Say It Has More Upside – Here’s Why

We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme T... Full story

Yahoo Finance • 11 days ago

This Medical Technology Leader Sees Profit Growth Topping 44%

The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter. Continue Reading View Comments... Full story

Yahoo Finance • 12 days ago

J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis

[FDA Headquarters] The U.S. FDA on Thursday granted traditional approval for Darzalex Faspro, an injectable version of the multiple myeloma therapy daratumumab, developed by J&J (JNJ [https://seekingalpha.com/symbol/JNJ]) and Halozyme The... Full story

Yahoo Finance • 15 days ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (B... Full story

Yahoo Finance • 25 days ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food an... Full story

Yahoo Finance • 25 days ago

Halozyme Therapeutics prices $1.3 billion convertible notes

* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) priced [https://seekingalpha.com/pr/20298440-halozyme-therapeutics-inc-announces-pricing-of-private-offering-of-650-million-of-convertible] $650 million aggregate prin... Full story

Yahoo Finance • last month

H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associat... Full story

Yahoo Finance • 2 months ago

Xencor Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue? Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Halozyme names Cortney Caudill as COO

* Halozyme Therapeutics (NASDAQ:HALO [https://seekingalpha.com/symbol/HALO]) said Cortney Caudill was appointed as Senior Vice President, Chief Operating Officer of the company, effective immediately. * Caudill, aged 49, has served as... Full story

Yahoo Finance • 2 months ago

Where is Halozyme Therapeutics (HALO) Headed According to Analysts?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now. On August 18, Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $80 from $75, keeping an O... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors

In value investing, the search for undervalued stocks with strong basic foundations remains a central strategy. This approach, started by Benjamin Graham and later improved by investors like Warren Buffett, focuses on finding companies tra... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum

The method used to find good investment chances joins Mark Minervini’s strict Trend Template with a concentration on strong-growth momentum. Minervini’s method highlights stocks showing solid technical condition, characterized by upward-mo... Full story

Yahoo Finance • 3 months ago

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals

Investors seeking growth opportunities at reasonable valuations often turn to strategies that balance expansion potential with financial prudence. The "Affordable Growth" approach specifically targets companies demonstrating solid growth p... Full story

Yahoo Finance • 3 months ago

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

On Wednesday, KalVista Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 82, up from 79 the day before. Is KalVista Pharmaceutic... Full story

Yahoo Finance • 3 months ago

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen

In growth investing, few strategies have received as much notice as the one described in Louis Navellier’s 2007 book, _The Little Book That Makes You Rich_. The approach focuses on finding companies showing solid, quickening growth through... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global markets saw an incredible but volatile second quarter, shift... Full story

Yahoo Finance • 3 months ago

Health care stocks with the largest net increases in hedge fund popularity – Goldman Sachs

[Medical industry stock market graph chart] Rasi Bhadramani Hedge funds increased their overweight positioning in health care (NYSEARCA:XLV [https://seekingalpha.com/symbol/XLV]) despite a 7% decline in the sector during the second quarte... Full story

Yahoo Finance • 3 months ago

Halozyme Therapeutics stock reaches all-time high at 70.57 USD

Halozyme Therapeutics (NASDAQ:HALO) Inc. stock has reached an all-time high, hitting 70.57 USD. The milestone caps an impressive year-to-date gain of 44.24%, significantly outperforming its 15.48% one-year return. According to InvestingPr... Full story

Yahoo Finance • 4 months ago

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors

Investors looking for growth opportunities at fair prices often consider the "Affordable Growth" strategy, which finds stocks with solid growth potential while keeping strong financial health and profitability, all at a valuation that does... Full story